CURCUMIN CYCLODEXTRIN COMBINATION FOR PREVENTING OR TREATING VARIOUS DISEASES

• US 20100179103A1
• Filed: 06/22/2009
• Published: 07/15/2010
• Est. Priority Date: 07/21/2008
• Status: Abandoned Application

• Current Assignee: Ketan Desai
• Original Assignee: Ketan Desai
• Inventors: Desai, Ketan
• Application Number:
  US12/488,781
• Publication Number:
  US 20100179103A1
• Time in Patent Office: Days
• US Class Current: 514/58
• CPC Class Codes: A61K 47/6951 using cyclodextrin cyclodextrins used as simple excipients A61K47/40
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C08B 37/0015 Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Abstract

Curcumin has shown anti-inflammatory and anti-angiogenic properties that could be useful in treating various diseases such as those of rheumatology and oncology. However, curcumin is very poorly absorbed and has a very low bioavailability. This patent describes a method of increasing the delivery of curcumin by complexing it with cyclodextrins. Cyclodextrins are well known in the food industry and have been used to carry other drugs to increase bioavailability. The new combination of cyclodextrins and curcumin has been tested in pre-clinical inflammation models where it has demonstrated efficacy superior to both the positive control and curcumin.

Claims

1. A curcumin cyclodextrin complex having enhanced bioavailability and/or efficacy, irrespective of the ratio of curcumin and cyclodextrin

2. A curcumin composition as recited in claim 1, wherein the curcumin is selected from the group consisting of curcumin, tetrahydrocurcumin, demethoxycurcumin, bisdemethoxycurcumin, curcumin esters, and mixtures thereof.

3. A curcumin composition as recited in claim 1, wherein the curcuminoid comprises a curcumin pro-drug.

4. A cyclodextrin as recited in claim 1, wherein the cyclodextrin is alpha, beta, or gamma cyclodextrin.

5. A cyclodextrin as recited in claim 1, wherein the cyclodextrin may be amorphous or crystalline.

6. A curcumin cyclodextrin complex as recited in claim 1, wherein the complex has the form of a solid powder, liquid, microemulsion, solid lipid nanoparticles, microencapsulated oil, or gel, and is suitable for parenteral, topical or enteral administration.

7. A method of use of the complex as recited in claim 1 to treat diseases including but not limited to neurological diseases such as Alzheimers, autoimmune or inflammatory or allergic diseases such as asthma and rheumatoid arthritis, oncologic diseases, respiratory system diseases such as chronic obstructive lung disease, dermatologic diseases, cardiovascular diseases such as hyperlipidemia and coronary artery disease, gastrointestinal hepatic and pancreatic diseases such as inflammatory bowel disease, metabolic diseases such as diabetes, urologic, infectious diseases and for wound healing.

8. A method of use as recited in claim 1 wherein the administration can be oral, topical, parenteral, nasal, inhalational, or suppository.

9. A method of use as recited in claim 1 where the complex is administered concurrently with any therapy for the treatment or prevention of diseases as mentioned in 7.

10. A method of use as recited in claim 1 where the complex is used with a device such as coating a coronary artery stent.